

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48		A1	(11) International Publication Number: WO 99/61060
			(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/CA99/00438 (22) International Filing Date: 13 May 1999 (13.05.99) (30) Priority Data: 2,238,257 22 May 1998 (22.05.98) CA (71) Applicant (for all designated States except US): UNIVER- SITE DE MONTREAL [CA/CA]; 2900 Edouard-Montpetit, Montréal, Québec H3T 1J4 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): NABI, Ivan, R. [CA/CA]; 5505 avenue Bourret, Montréal, Québec H3X 1J5 (CA). (74) Agents: COTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>	
(54) Title: CONJUGATES OF AN AMF LIGAND AND A CYTOTOXIC MOLECULE FOR USE IN CANCER THERAPY			
(57) Abstract			
The present invention relates to a therapeutical conjugate to specifically kill motile cells, which comprises a first molecule which binds to autocrine motility factor receptor (AMF-R) attached to a second toxic molecule to kill said motile cells.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CONJUGATES OF AN AMF LIGAND AND A CYTOTOXIC MOLECULE FOR USE IN CANCER THERAPY

BACKGROUND OF THE INVENTION(a) Field of the Invention

5 The invention relates to the use of the endocytosis or internalization of autocrine motility factor receptor (AMF-R) as a means to target motile cells, such as metastatic tumor cells. The invention also relates to AMF-conjugates for therapeutical treatment.

10 (b) Description of Prior Art

 Expression of autocrine motility factor receptor (AMF-R) is associated with the acquisition of motile and metastatic properties by tumor cells (Nabi, I.R. et al. (1992) Cancer Met. Rev. 11, 5-20; Silletti, S. et al. (1996) Am. J. Pathol. 148, 1649-1660). AMF-R is a cell surface receptor which mediates motility stimulation by its 55 kD polypeptide ligand, AMF, recently shown to be homologous to phosphohexose isomerase. Expression of AMF-R has been shown to be associated with tumor malignancy and inversely with patient survival associating AMF-R expression with poor prognosis. AMF-R internalizes its ligand via both clathrin-dependent and clathrin-independent pathways.

 Transduction of the AMF motility signal occurs via receptor phosphorylation, a pertussis-toxin sensitive G-protein, inositol phosphate production, tyrosine kinase and protein kinase C activation and production of the lipoxxygenase metabolite 12-HETE (Silletti, S. et al. (1996) Am. J. Pathol. 148, 1649-1660). AMF-R is localized not only to the plasma membrane but also to an intracellular tubular organelle, the AMF-R tubule (Nabi, I.R. et al. (1992) Cancer Met. Rev. 11, 5-20; Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471). AMF-R tubules are distinct from endosomes and lysosomes; by post-embedding immunoelectron microscopy AMF-R is present primarily in smooth tubules which

extend from ribosome-studded cisternae however AMF-R tubules do not colocalize with ERGIC-53, a marker for the ER-Golgi intermediate compartment (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471; Wang et al., 5 1997). Following treatment with ilimaquinone, AMF-R tubules acquire a fenestrated morphology typical of smooth ER suggesting that the AMF-R tubule is a distinct smooth subdomain of the endoplasmic reticulum (Wang, H.-J. et al. (1997) J. Cell Sci. 110, 3043-10 3053). The intracellular distribution of this cell surface receptor to smooth ER implicates AMF-R recycling in its function in cell motility and tumor cell metastasis.

It would be highly desirable to be provided with 15 a means to target motile cells, such as metastatic tumor cells.

SUMMARY OF THE INVENTION

One aim of the present invention is to provide a 20 means to target motile cells, such as metastatic tumor cells.

Another aim of the present invention is to provide the use of the endocytosis or internalization of autocrine motility factor receptor (AMF-R) as a means 25 to target motile cells, such as metastatic tumor cells.

In accordance with the present invention, it is demonstrated that AMF-R is concentrated at the cell surface within smooth plasmalemmal vesicles or caveolae and that AMF is internalized via a non-clathrin pathway 30 to intracellular smooth ER tubules. The results of the present invention identify an AMR-R-mediated clathrin-independent internalization pathway to the endoplasmic reticulum which may be implicated in AMF-R function in tumor cell motility and metastasis.

35 In accordance with the present invention there is provided a therapeutical conjugate to specifically

kill motile cells, which comprises a first molecule which binds to autocrine motility factor receptor (AMF-R) attached to a second toxic molecule to kill said motile cells, such as metastatic tumor cells.

5 The preferred first molecule is AMF.

 The said second molecule includes, without limitation, plant toxins, bacterial toxins, fungal toxins, drugs, and enzymes for treating prodrugs.

10 The preferred plant toxin includes, without limitation, ricin, abrin, modeccin, viscumin, pokeweed antiviral protein (PAP), saporin, gelonin, momoridin, trichosanthin, barley toxin, and bryodin.

15 The preferred bacterial toxin includes, without limitation, pseudomonas exotoxin (PE), and diphtheria toxin.

 The preferred fungal toxin includes, without limitation, α -sarcin, and restrictocin.

20 The preferred drug includes, without limitation, doxorubicin, 2-pyrrolinodoxorubicin, daunorubicin, methotrexate, neocarzinostatin, mitomycin C, calicheamicin, and vinca alkaloids.

 The preferred enzyme includes, without limitation, carboxypeptidase, and alkaline phosphatase.

25 In accordance with the present invention there is also provided the use of internalization of autocrine motility factor receptor (AMF-R) to target motile cells, which comprises at least one molecule which binds to autocrine motility factor receptor (AMF-R) and is internalized by motile cells, such as metastatic
30 tumor cells.

 In accordance with the present invention there is also provided a method to specifically kill cancer cells *in vitro* and/or *in vivo*, which comprises administering an effective amount of the conjugate of the present
35 invention.

The cells *in vitro* may be leukemias purging cells whereas the cells *in vivo* may be metastatic tumor cells.

5 **BRIEF DESCRIPTION OF THE DRAWINGS**

Fig. 1 illustrates the electron microscopic localization of AMF-R in NIH-3T3 fibroblasts and HeLa cells;

10 Fig. 2 illustrates the colocalization of AMF-R and caveolin by confocal microscopy;

Fig. 3 illustrates bAMF and anti-AMF-R mAb colocalize on the cell surface;

Fig. 4 illustrates the internalization of bAMF to AMF-R tubules;

15 Fig. 5 illustrates the localization of internalized bAMF to AMF-R tubules by confocal microscopy;

Fig. 6 illustrates the electron microscopy of the internalization pathway of bAMF;

20 Fig. 7 illustrates G25 Sephadex™ chromatography of AMF-doxorubicin mixture following conjugation with 0.02% glutaraldehyde;

Fig. 8 illustrates the cell toxicity of a AMF-doxorubicin conjugate in accordance with one embodiment of the present invention.

25

DETAILED DESCRIPTION OF THE INVENTION

Autocrine motility factor receptor (AMF-R) is a cell surface receptor which is also localized to a smooth subdomain of the endoplasmic reticulum (ER), the
30 AMF-R tubule. By post-embedding immunoelectron microscopy, AMF-R concentrates within smooth plasmalemmal vesicles or caveolae in both NIH-3T3 fibroblasts and HeLa cells. By confocal microscopy, cell surface AMF-R labeled by the addition of anti-AMF-R antibody to
35 viable cells at 4°C exhibits partial colocalization with caveolin confirming the localization of cell sur-

face AMF-R to caveolae. Labeling of cell surface AMF-R by either anti-AMF-R antibody or biotinylated AMF (bAMF) exhibits extensive colocalization and after a pulse of 1-2 hours at 37°C, bAMF accumulates in densely labeled perinuclear structures as well as fainter tubular structures which colocalize with AMF-R tubules. After a subsequent 2-4 hour chase bAMF is localized predominantly to AMF-R tubules. Cytoplasmic acidification, blocking clathrin-mediated endocytosis, results in the essentially exclusive distribution of internalized bAMF to AMF-R tubules. By confocal microscopy, the tubular structures labeled by internalized bAMF show complete colocalization with AMF-R tubules. bAMF internalized in the presence of a 10-fold excess of unlabeled AMF labels perinuclear punctate structures, which are therefore the product of fluid phase endocytosis, but not AMF-R tubules demonstrating that bAMF targeting to AMF-R tubules occurs via a receptor-mediated pathway. By electron microscopy, bAMF internalized for 10 minutes is located to cell surface caveolae and after 30 minutes is present within smooth and rough ER tubules. AMF is therefore internalized via a receptor-mediated clathrin-independent pathway to smooth endoplasmic reticulum. The steady state localization of AMF-R to caveolae implicates these cell surface invaginations in AMF-R endocytosis.

MATERIALS AND METHODS

Cells and Cell Culture

NIH-3T3 fibroblasts obtained from the ATCC were cloned and a highly spread clone was used for these studies. HeLa and NIH-3T3 cells were grown in an air-5% CO₂ incubator at constant humidity in Dulbecco's minimum essential medium (DMEM) containing non-essential amino acids, vitamins, glutamine and a penicillin-

streptomycin antibiotic mixture (Gibco, Burlington, Ontario) supplemented with 5% fetal calf serum (Immuno-corp, Montreal, Quebec) for HeLa or 10% calf serum (Gibco, Burlington, Ontario) for NIH-3T3 cells.

5 Antibodies and chemicals

Monoclonal antibody against AMF-R was used in the form of concentrated hybridoma supernatant (Nabi, I.R. et al. (1992) Cancer Met. Rev. 11, 5-20). Rabbit anti-caveolin polyclonal antibody was purchased from
10 Transduction Laboratories (Lexington, KY), rabbit anti-biotin antibody from Sigma (St. Louis, Missouri), and rat anti-LAMP-1 from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City). Secondary antibodies conjugated to either fluorescein, Texas Red
15 or 12 nm gold particles and streptavidin conjugated to fluorescein or Texas Red were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Texas Red conjugated human diferric transferrin was kindly provided by Dr. Tim McGraw (Columbia University, New York,
20 NY). Streptavidin conjugated to 10 nm gold particles was purchased from Sigma. The secondary antibodies were designed for use in multiple labeling studies and no interspecies cross-reactivity was detected. To detect antibodies to AMF-R, secondary antibodies specific for
25 the μ chain of rat IgM were used.

Rabbit phosphohexose isomerase was purchased from Sigma and biotinylated with NHS-LC-biotin (Pierce, Rockford, Illinois) according to the manufacturer's instructions. To assess its purity, biotinylated phos-
30 phohexose isomerase was separated by SDS-PAGE, transferred to nitrocellulose, probed with horseradish per-

oxidase conjugated streptavidin (Jackson ImmunoResearch Laboratories) and revealed by chemiluminescence.

Immunofluorescence

Cells were plated on glass cover slips 2 days
5 prior to each experiment at a concentration of 30,000
cells/35 mm dish. For AMF-R surface labeling, the cells
were incubated in DMEM minus bicarbonate supplemented
with 25 mM Hepes pH 7.2 and 2.5% serum for 15 min at
4°C prior to labeling with anti-AMF-R primary antibody
10 or biotinylated AMF at 4°C for 30 min. The cells were
washed at 4°C and then fixed with 3% paraformaldehyde
in phosphate buffered saline (pH 7.4) supplemented with
0.1 mM Ca^{++} and 1 mM Mg^{++} (PBS/CM) for 15 min at room
temperature. For caveolin labeling, after AMF-R surface
15 labeling at 4°C and fixation as above, the cells were
permeabilized with 0.2% Triton X-100 for 10 min, then
extensively washed with PBS/CM containing 1% BSA. The
cells were incubated with rabbit anti-caveolin polyclo-
nal antibodies, washed, and then incubated with FITC
20 goat anti-rat IgM to reveal anti-AMF-R and Texas Red
donkey anti-rabbit IgG to reveal anti-caveolin. Cell
surface labeling with biotinylated AMF was revealed
with rabbit anti-biotin antibody and fluorescent anti-
rabbit secondary antibody.

25 For the AMF internalization studies, NIH-3T3
cells were pulsed with biotinylated AMF (~250-500
 $\mu\text{g/ml}$) and chased at 37°C for the indicated periods of
time prior to fixation by the addition of precooled (-
80°C) methanol/acetone directly to the cells. After
30 fixation, internalized bAMF was revealed with Texas Red
streptavidin and lysosomes and AMF-R tubules by anti-

LAMP-1 and anti-AMF-R antibodies, respectively, followed by the corresponding FITC-conjugated secondary antibodies. Disruption of clathrin coated pits and vesicles by cytoplasmic acidification was performed
5 essentially as previously described (Heuser, J. (1989) J. Cell Biol. 108, 401-411). NIH-3T3 cells were pre-treated with acidification medium (DMEM containing 5% calf serum and 50mM MES pH 5.5) for 15 minutes at 37°C prior to addition of bAMF in acidification medium for
10 one hour at 37°C. To ensure that cellular acidification blocked clathrin-mediated endocytosis, Texas Red transferrin (50 µg/ml) was added to cells in regular or acidification medium for 30 minutes at 37°C after which the cells were fixed with 3% paraformaldehyde.

15 After labeling the coverslips were mounted in Airvol (Air Products and Chemicals Inc., Allentown, PA) and viewed in a Zeiss Axioskop fluorescent microscope equipped with a 63X Plan Apochromat objective and selective filters. Confocal microscopy was performed
20 with the 60X Nikon Plan Apochromat objective of a dual channel BioRad 600 laser scanning confocal microscope equipped with a krypton/argon laser and the corresponding dichroic reflectors to distinguish fluorescein and Texas Red labeling. Confocal images were printed using
25 a Polaroid TX 1500 video printer.

Electron microscopy

Post-embedding immunolabeling for AMF-R was performed as previously described (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471). Cells grown on
30 petri dishes were rinsed and incubated at 37°C in Ringer's solution for 15 minutes before fixing in Ringer's solution containing 2% paraformaldehyde and

0.2% glutaraldehyde for 30 minutes at 37°C. The fixed cells were rinsed in PBS/CM, scraped from the petri dish and collected by centrifugation. The cell pellet was post-fixed for 30 minutes with 1% osmium tetroxide in PBS/CM containing 1.5% potassium ferrocyanide (reduced osmium), dehydrated and embedded in LR-White resin. Ultra-thin sections (80 nm) were blocked with 2% BSA, 0.2% gelatin in PBS/CM for 1 hour, and then incubated at room temperature with anti-AMF-R antibody for 1 hour followed by 12 nm gold conjugated goat anti-rat antibodies for 1 hour. The sections were then stained with 5% uranyl acetate and examined in a Philips 300 electron microscope. The numerical density of gold particles associated with plasma membrane, caveolae, clathrin coated pits and vesicles, smooth tubules and vesicles, and rough ER was determined. The length of the limiting membrane of the indicated organelles was measured using a Sigma-Scan measurement system and the gold particles associated with these organelles counted. Rough ER was defined by the presence of a linear array of membrane-associated ribosomes. Smooth vesicles attached to the plasma membrane or within 100 nm of the plasma membrane were considered to be caveolae. Control labeling with non-immune rat IgM antibodies was analyzed similarly.

To follow the endocytic pathway of AMF by electron microscopy, biotinylated AMF was internalized as described for the fluorescence studies and detected by postembedding labeling with streptavidin conjugated to 10 nm gold as described above. No labeling was observed in the absence of biotinylated AMF.

Expression of AMF and AMF-R in normal tissue

The AMF/PHI polypeptide has been shown to be expressed in various tissues in the mouse including muscle, salivary gland, brain, liver and kidney. PHI mRNA exhibits particularly high expression in the muscle, brain and kidney of adult mouse, rat and chicken. PHI is identical to neuroleukin, which increases the survival of cultured sensory neurons and which is secreted by lectin-stimulated T cells and induces maturation of B-cells into antibody secreting cells, and to maturation factor, which induces the differentiation of human myeloid cells into monocytes. Consistent with its identity with neuroleukin and maturation factor, AMF activity has been detected in rheumatoid synovial fluid. Therefore, in addition to its enzymatic activity, the secreted PHI polypeptide functions as a neurotrophic factor, a lymphokine and a motility factor.

In the studies of AMF-R expression in bladder, colorectal, gastric, skin and esophageal cancers as well as in breast carcinoma, AMF-R was expressed not at all or at significantly reduced levels in adjacent normal tissue. Studies performed in the Nabi laboratory have shown that while AMF-R is expressed in brain, liver and lung but not kidney and muscle of young (postnatal day 5 and 12) rats, AMF-R expression is significantly reduced or absent in these tissues in the adult. In the cerebellum, AMF-R was localized to cerebellar neurons, including Purkinje cells, and may play a role in neuronal plasticity and establishment of neuronal contacts during development. Cell and tissue specific expression of AMF and AMF-R may regulate their motile activity during development; deregulation of the

expression of AMF and its receptor during tumorigenesis may contribute to the acquisition of motile and invasive properties by tumor cells. The dramatically decreased expression of AMF-R in normal cells in the adult certainly supports its utility as a target for tumor therapy.

Localization of AMF-R to cell surface caveolae

By post-embedding immunoelectron microscopy in NIH-3T3 and HeLa cells, AMF-R is primarily localized to smooth intracellular membranous tubules (Figs. 1A,D), similar in morphology to those previously described in MDCK cells (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471). HeLa (Figs. 1A,B,C) and NIH-3T3 (Figs. 1D,E,F) cells were post-embedding immunolabeled with anti-AMF-R and 12-nm gold-conjugated anti-rat IgM secondary antibodies. Typical AMF-R labeling of smooth tubules (Figs. 1A,D, arrows) and cell surface caveolae (Figs. 1B,C,E,F, arrowheads) is shown. PM: plasma membrane. Bar = 0.2 μ m.

At the cell surface, AMF-R label localizes to smooth invaginations of the plasma membrane morphologically equivalent to caveolae (Figs. 1B,C,E,F). Quantification of the labeling revealed that the predominant AMF-R label is localized to smooth tubules and vesicles, flat regions of the plasma membrane and caveolae (Table 1).

Table 1

**Localization of AMF-R in HeLa and NIH-3T3 cells by
immunoelectron microscopy**

	Smooth tubules and vesicles	Rough endoplasmic reticulum	Flat plasma membrane	Caveolae	Clathrin- coated pits and vesicles
HeLa					
AMF-R					
# gold particles	660	34	147	52	3
μm membrane	328.5	187.5	245.6	14.6	19.3
gold particles/ μm	2.01 ± 0.15	0.18 ± 0.04	0.60 ± 0.08	3.56 ± 0.53	0.16 ± 0.13
Control					
# gold particles	83	6	25	3	1
μm membrane	307.5	95.2	211.0	16.1	5.0
gold particles/ μm	0.27 ± 0.08	0.06 ± 0.03	0.12 ± 0.05	0.19 ± 0.10	0.20 ± 0.21
NIH-3T3					
AMF-R					
# gold particles	640	74	296	44	2
μm membrane	432.6	308.9	308.8	28.8	34.7
gold particles/ μm	1.48 ± 0.10	0.24 ± 0.06	0.96 ± 0.10	1.53 ± 0.30	0.06 ± 0.06
Control					
# gold particles	33	7	10	4	2
μm membrane	303.1	109.8	138.1	31.7	6.2
gold particles/ μm	0.11 ± 0.02	0.06 ± 0.03	0.07 ± 0.03	0.13 ± 0.06	0.32 ± 0.18

5 Gold particles associated with the indicated membrane organelles were counted and the density per μm membrane length determined. Control labeling was determined using a nonimmune rat IgM antibody (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471).

10 While specific label was previously detected in the rough ER of MDCK cells (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471), the density of labeling of rough ER tubules in NIH-3T3 and HeLa cells is reduced and at control levels. The density of AMF-R labeling of
15 caveolae is equal to that of intracellular smooth

tubules and vesicles in NIH-3T3 cells and greater than that of intracellular smooth tubules and vesicles in HeLa cells and essentially no AMF-R label is found within clathrin coated pits and vesicles. The density of AMF-R labeling in caveolae is increased relative to flat regions of the plasma membrane. However, based on the total number of gold particles at the plasma membrane, only 13% of cell surface AMF-R in NIH-3T3 and 26% in HeLa cells is found within caveolae.

10 To assess whether cell surface AMF-R colocalizes with caveolin, viable NIH-3T3 cells were surface labeled for AMF-R by the addition of anti-AMF-R antibodies to viable cells at 4°C (Nabi, I.R. et al. (1992) Cancer Met. Rev. 11, 5-20) and then double immunofluorescently labeled after fixation and permeabilization with antibodies to caveolin (Fig. 2). Viable NIH-3T3 cells were labeled for cell surface AMF-R at 4°C (Fig. 2A) and for caveolin after fixation and permeabilization (Fig. 2B). To demonstrate the colocalization of AMF-R and caveolin, confocal images from both fluorescent channels were superimposed (Fig. 2C, AMF-R in green and caveolin in red) and colocalization appears in yellow. Bar = 20 μ m.

25 While the punctate AMF-R surface label (Fig. 2A) did not completely colocalize with the finer caveolin labeling (Fig. 2B), confocal microscopy clearly revealed distinct points and patterns labeled for both cell surface AMF-R and caveolin (Fig. 2C, yellow). Peripheral regions densely labeled for both AMF-R and caveolin were frequently observed. The partial colocalization of cell surface AMF-R with caveolin is consistent with the fact that, based on the EM data, only 13% of cell surface AMF-R was localized within the caveolae of NIH-3T3 cells.

Internalization of AMF

The ligand for AMF-R, AMF, is homologous to phosphohexose isomerase (Watanabe, H. et al. (1996) Cancer Res. 56, 2960-2963). Phosphohexose isomerase (referred to here as AMF) was biotinylated and after separation by SDS-PAGE revealed a single major band after revelation of the blots with streptavidin-HRP (Fig. 3A). bAMF (phosphohexose isomerase) migrated as a single band in protein blots revealed with HRP-streptavidin (Fig. 3A). Confocal imaging of cell surface labeling of viable NIH-3T3 cells at 4°C with bAMF (Fig. 3B) or anti-AMF-R antibody (Fig. 3C). Confocal images from both fluorescent channels were superimposed (Fig. 3D; bAMF in green and AMF-R in red) and revealed a significant degree of colocalization in yellow. Bar = 20 μ m.

Cell surface labeling of NIH-3T3 cells by the addition of both biotinylated AMF (bAMF) (Fig. 3B) and anti-AMF-R at 4°C (Fig. 3C) revealed a high degree of colocalization (Fig. 3D, yellow) demonstrating that AMF and antibodies to AMF-R recognize the same receptor. The presence of spots labeled exclusively with either bAMF or anti-AMF-R may be due to the fact that the two were added together and may compete for the same site.

Pulse labeling of NIH-3T3 cells with bAMF for one or two hours resulted in the ability to detect both punctate structures as well as fainter tubular structures which colocalized with AMF-R tubules (Figs. 4A,B). NIH-3T3 cells were pulse labeled with bAMF at 37°C for one hour (Figs. 4A, B), for two hours and chased for 4 hours (Figs. 4C, D) or for one hour in medium acidified to pH 5.5 to disrupt clathrin-mediated endocytosis (Figs. 4E, F). After fixation with methanol/acetone, cells were double labeled with Texas Red-streptavidin to reveal bAMF (Figs. 4A, C, E) and anti-AMF-R mAb and FITC-conjugated anti-rat secondary anti-

body to reveal AMF-R labeling (Figs. 4B, D, F). To ensure that cellular acidification disrupted clathrin-mediated endocytosis of transferrin receptor, NIH-3T3 cells were incubated at 37°C with Texas Red transferrin for 30 minutes in regular medium (Fig. 4G) or in medium acidified to pH 5.5 (Fig. 4H). Bar = 20 μ m.

Under these conditions, the extent of punctate and tubular labeling varied between cells. Fibrillar labeling of bAMF was also observed and has been determined to be localized to the cell surface. An extended chase of 2 or 4 hours after a two hour pulse resulted in decreased punctate labeling and the accumulation of bAMF labeling in tubular structures which colocalized with AMF-R tubules (Figs. 4C,D). The vast majority of the cells exhibited predominantly intracellular tubular labeling as well as cell surface fibrillar labeling. Following treatment of cells with acidified medium (pH 5.5) and disruption of clathrin coated pits and vesicles (Heuser, J. (1989) J. Cell Biol. 108, 401-411), bAMF internalized for one hour is localized to intracellular AMF-R tubules (Figs. 4E,F). In the acidified medium, internalized transferrin did not cluster in the perinuclear recycling compartment demonstrating that the acidification procedure did indeed disrupt clathrin-mediated endocytosis (Figs. 4G,H). bAMF is therefore internalized via a clathrin-independent endocytic pathway to the smooth ER.

The colocalization of bAMF labeled tubules with AMF-R tubules was confirmed by confocal microscopy (Fig. 5). NIH-3T3 cells were pulse labeled with bAMF at 37°C for one hour in regular medium (Figs. 5A-F), for one hour in medium acidified to pH 5.5 to disrupt clathrin-mediated endocytosis (Figs. 5G-I), or in regular medium in the presence of 10-fold excess unlabeled AMF (Figs. 5J-L) prior to fixation with methanol/acetone. bAMF was revealed with Texas Red-strepta-

vidin (Figs. 5A, D, G, J), and AMF-R (Figs. 5B, H, K) or LAMP-1 (Fig. 5E) labeled with the appropriate primary antibodies and FITC-conjugated secondary antibodies. Confocal images from both fluorescent channels were superimposed (Figs. 5C, I, L: bAMF in red and AMF-R in green; F: bAMF in red and LAMP-1 in green) and colocalization appears in yellow. Bar = 10 μ m.

Following a 1 hour bAMF internalization, internalized bAMF is localized to tubular structures which colocalize with AMF-R tubules (Figs. 5A-C) as well as to punctate structures which exhibit partial colocalization with LAMP-1 positive lysosomes (Figs. 5D-F). As seen here, the intense punctate labeling can hide the fainter tubular labeling of bAMF in some cells (Figs. 4A, 5D). In acidification medium, the vast majority of bAMF labeling, aside from cell surface fibrils, is localized to tubules which colocalize with AMF-R tubules (Figs. 5G-I). bAMF internalized for 1 hour in the presence of 10-fold excess unlabeled AMF is localized only to punctate structures and no labeling of AMF-R tubules can be detected (Figs. 5J-L). While the extent of tubular labeling of bAMF varies between cells under control conditions (Figs. 5A,D), in the presence of excess unlabeled AMF the localization of bAMF to AMF-R tubules is never observed (Figs. 5J-L). bAMF internalization to intracellular AMF-R tubules therefore occurs via a receptor-mediated process. The inability of excess AMF to block bAMF internalization to punctate perinuclear structures, which exhibit partial colocalization with LAMP-1 labeled lysosomes, demonstrates that this labeling is not saturable and corresponds to non-specific fluid phase uptake. The disappearance of lysosomal labeling following extended chase times (Fig. 4C,D) is therefore most likely due to lysosomal degradation of fluid phase internalized bAMF.

The location of biotinylated AMF internalized at 37°C was determined by post-embedding electron microscopy with streptavidin-10 nm gold. Following a 10 minute pulse biotinylated AMF could be detected in caveolae (Figs. 6A,B). NIH-3T3 cells were pulsed with bAMF at 37°C for 10 (Figs. 6A,B,H) or 30 minutes (Figs. 6C,D,E,F,G,I). The localization of bAMF was revealed by postembedding labeling with 10 nm gold-conjugated streptavidin. After 10 minutes, bAMF is localized to cell surface caveolae (Figs. 6A,B). After a 30 minute pulse, bAMF is localized to caveolae and smooth vesicles (Figs. 6C,D) and also appears in intracellular membranous tubules (Figs. 6E,F,G) including distinctive smooth (Fig. 6E) and rough (Fig. 6F) ER elements. bAMF labeling of dense lysosomal structures is also detected (Fig. 6H,I). Bar = 0.1 μ m.

Following a 30 minute pulse, both caveolae and intracellular smooth and rough ER elements were labeled (Figs. 6C-G). Dense structures morphologically equivalent to lysosomes are also labeled and presumably correspond to the perinuclear structures densely labeled for internalized bAMF by immunofluorescence (Figs. 6H,I).

AMF-R localization to caveolae

By post-embedding immunoelectron microscopy AMF-R is localized to morphologically identifiable caveolae as well as to smooth ER tubules (Fig. 1; Table 1). In contrast to polarized epithelial MDCK cells (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471), labeling of rough ER tubules was not above background in either NIH-3T3 or HeLa cells indicating that AMF-R is a specific marker for smooth ER in these two cell types. The localization of AMF-R to caveolae was confirmed by the colocalization of cell surface AMF-R, labeled by the addition of anti-AMF-R to viable cells at 4°C, with caveolin by confocal fluorescence microscopy (Fig. 2).

By both postembedding immunoelectron microscopy and confocal double labeling with caveolin, only a minor portion of cell surface AMF-R actually distributes to caveolae identified either morphologically or by the presence of caveolin. Based on the labeling of AMF-R by immunoelectron microscopy, only about 5% of total cellular AMF-R is actually localized to caveolae (Table 1).

Transduction of the AMF motility signal is mediated by a pertussis-toxin sensitive G protein, phosphorylation of AMF-R and both protein kinase C and tyrosine kinase activities (Silletti, S. et al. (1996) Am. J. Pathol. 148, 1649-1660). Caveolar cell surface domains have been proposed to be plasma membrane regions which serve to assemble molecules involved in receptor-mediated signal transduction, including heterodimeric G-proteins, protein kinase C and tyrosine kinases (Lisanti, M.P. et al. (1994) Trends Cell Biol. 4:231-235). The involvement of heterotrimeric G proteins as well as tyrosine kinase and protein kinase C activities in transduction of the AMF motility signal is consistent with the localization of AMF-R to cell surface caveolae.

Clathrin-independent internalization of AMF-R to smooth ER tubules

The presence of AMF-R both at the cell surface and within an intracellular ER-associated organelle suggested that the receptor recycles between these two cellular sites (Nabi, I.R. et al. (1992) Cancer Met. Rev. 11, 5-20; Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471). The fact that the density of AMF-R labeling within caveolae is equivalent to (NIH-3T3) or greater than (HeLa) that of smooth vesicles and tubules is consistent with the concentration of AMF-R within caveolae prior to vesicle budding and fusion with AMF-R tubules (Table 1).

AMF exhibits sequence identity to phosphohexose isomerase (Watanabe, H. et al. (1996) Cancer Res. 56, 2960-2963). Biotinylated phosphohexose isomerase or bAMF colocalizes with cell surface AMF-R labeled with antibodies to AMF-R at 4°C and is endocytosed by cells at 37°C to tubules which colocalize with smooth ER AMF-R tubules by confocal microscopy and to morphologically identifiable ER tubules by electron microscopy. bAMF internalization to smooth ER tubules is a receptor-mediated process as it can be blocked by the presence of excess unlabeled AMF. Cellular acidification, which specifically blocks clathrin mediated endocytosis, disrupts the internalization of transferrin, but not that of bAMF to AMF-R tubules, demonstrating that AMF-R is internalized to AMF-R tubules via a non-clathrin endocytic pathway. Under the conditions used in these experiments, internalization of bAMF to lysosomal structures is also observed. This lysosomal labeling is observed even in the presence of excess unlabeled AMF indicating that it is not receptor-mediated and due to fluid phase uptake. We have therefore identified a clathrin-independent AMF-R-mediated endocytic pathway which targets bAMF to the endoplasmic reticulum. The localization of AMF-R and internalized bAMF to cell surface caveolae by electron microscopy implicates these smooth invaginations of the plasma membrane in the endocytosis of AMF-R to the smooth ER subdomain for which it is a marker (Benlimame, N. et al. (1995) J. Cell Biol. 129, 459-471; Wang, H.-J. et al. (1997) J. Cell Sci. 110, 3043-3053).

Role of caveolae in AMF-R internalization

Whether caveolae are involved in endocytic processes in non-endothelial cells remains a controversial subject and whether clathrin-independent internalization routes involve caveolae or clathrin-coated pits

without the clathrin is not clear (van Deurs, B. et al. (1993) Trends Cell Biol. 3, 249-251).

The receptor-mediated endocytosis of bAMF not to endosomes and lysosomes but to the ER certainly suggests that bAMF endocytosis is not mediated by uncoated clathrin vesicles. SV40 virus associates with caveolae and is internalized via smooth plasmalemmal vesicles to smooth tubules which are extensions of the ER (Kartenbeck, J. et al. (1989) J. Cell Biol. 109, 2721-2729). The internalization pathway of SV40 to the ER (Kartenbeck, J. et al. (1989) J. Cell Biol. 109, 2721-2729) is therefore remarkably similar to that of AMF-R described here and the localization of both AMF-R and SV40 to cell surface caveolae certainly implicates caveolae in this ER directed endocytic pathway. AMF activation of AMF-R may stimulate both transduction of the AMF motility stimulating signal and internalization of AMF-R, perhaps within the same cell surface caveolar domain.

AMF recycling and cell motility

The established role of AMF-R in cell motility and metastasis implicates AMF-R internalization, and subsequent recycling to the cell surface, in the motile process (Nabi, I.R. et al. (1992) Cancer Met. Rev. 11, 5-20; Silletti, S. et al. (1996) Am. J. Pathol. 148, 1649-1660). This recycling pathway stimulated by the cytokine, AMF, may represent a motility specific membrane targeting pathway.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

EXAMPLE I

AMF-R as a target for tumor therapy

The internalization of cancer specific ligands as a means to target metastatic tumor cells has previ-

ously been demonstrated for the BR96 antigen. The monoclonal antibody BR96 is specific for the Le^x polylectosamine carbohydrate antigen expressed abundantly on numerous carcinomas (Hellström, I. et al. 5 (1990) Cancer Res. 50:2183-2190). The BR96 antibody has been shown to be internalized via coated pits to multivesicular bodies, endosomes and finally to lysosomes where it is degraded (Garrigues, J. et al. (1993) Am. J. Pathol. 142: 607-622) Toxin conjugates of this 10 internalizing monoclonal antibody, such as BR96 doxorubicin immunoconjugates or *Pseudomonas* PE40 exotoxin fusion proteins, effected complete regression of xenografted human carcinomas in athymic mice (Friedman, P.N. et al. (1993) J. Immunol. 150: 3054-3061; Trail, 15 P.A. et al. (1993) Science 261:212-215).

Based on our knowledge to date, AMF-R is an attractive target for tumor therapy because (1) its expression is specifically associated with an essential element of tumor cell metastasis, cell motility, and it 20 exhibits minimal expression in normal cells, (2) its ligand is a common cellular protein, phosphohexose isomerase, which should not generate an immune response and which should exhibit a relatively long biological half-life, and (3) AMF is internalized by its receptor. 25 This last point is critical: it distinguishes the use of AMF-R as a target from many cell surface tumor markers and permits the internalization of a toxic compound. Normal and tumor cells will therefore be discriminated at two levels: receptor expression and 30 receptor internalization. We propose to prepare AMF-toxin conjugates and test their ability to kill breast cancer cells in vitro and test their toxicity in mice

with the goal to establish the viability of this approach to eliminate breast tumor cells *in vivo*.

EXAMPLE II

Preparation of AMF-toxin conjugates

5 PHI from mouse and human exhibit 87% homology indicating a high degree of sequence homology between species. For our studies of AMF internalization, we are currently using commercially available rabbit muscle PHI indicating that rabbit PHI is recognized by mouse
10 AMF-R (Benlimame et al., 1998, *Molec. Biol. Cell* 9: 1773-1786). We will initially prepare AMF-toxin conjugates with rabbit PHI since we have demonstrated its internalization in mouse NIH-3T3 fibroblasts for convenience (Benlimame et al., 1998, *Molec. Biol. Cell* 9:
15 1773-1786), however we have available the human PHI cDNA and are in the process of generating tagged recombinant human AMF. The purpose of these studies is to assess whether AMF-toxin conjugates can be used to target tumor cells and we will therefore conjugate AMF to
20 both the ricin α -chain and doxorubicin (DOX).

 Glutaraldehyde is a non-specific crosslinker which links amine groups and has previously been used to conjugate various proteins to DOX, including transferrin which is internalized by its receptor to early
25 endocytic compartments. We will use this relatively simple crosslinking approach to generate AMF conjugated to doxorubicin. AMF-DOX will be prepared by glutaraldehyde crosslinking as previously described for transferrin. The maximal glutaraldehyde concentration which
30 does not generate high molecular weight oligomers of AMF will be determined by SDS-PAGE. Using this gluta-

5 raldehyde concentration as well as moderately higher
and lower concentrations, AMF will be reacted with an
excess molar ratio (20:1) of DOX in order to favor DOX
conjugation to AMF. Reactive glutaraldehyde will be
10 neutralized with lysine and the DOX-AMF conjugate sepa-
rated from free DOX by either dialysis or Sephadex G25
chromatography. The extent of DOX incorporation into
the conjugate will be determined by spectrophotometry
at 495 nm (absorbance of DOX) after establishing con-
15 centration curves with known concentrations of free
DOX. Protein concentration of the conjugate will be
determined by spectrophotometry at 280 nm (for AMF
protein) in comparison with known concentrations of AMF
and taking into consideration potential interference of
20 DOX. Alternatively, protein concentration can be deter-
mined by densitometry of coomassie stained SDS-PAGE
gels in comparison with known amounts of unconjugated
AMF.

 While the use of glutaraldehyde should guarantee
20 successful crosslinking of AMF to toxin, its homofunc-
tional nature may result in the formation of high
molecular weight oligomers which may limit activity of
the AMF-DOX conjugate. If necessary, we will also con-
jugate AMF to the ricin α -chain using the heterobifunc-
25 tional crosslinker N-succinimidyl 3-(2-pyridyldi-
thio)propionate (SPDP) which contains NH_2 - and SH-reac-
tive domains and which has previously been used to form
ricin-antibody conjugate immunotoxins (Hellström, I. et
al. (1990) Cancer Res. 50:2183-2190). SPDP-conjugated
30 ricin α -chain will be reduced with DTT to generate free
SH sites which can attack the intact SH-reactive sites

of SPDP-PHI. Crosslinking will be assessed by SDS-PAGE under reducing and non-reducing conditions; successful crosslinking of the two proteins should result in the presence of a protein band of ~100-110 kD only under
5 non-reducing conditions. The crosslinking will also be performed using long chain LC-SPDP which contains an internal spacer between the reactive groups thereby reducing inefficient cross-linking due to steric hindrance. Ricin conjugated AMF can be purified from free
10 AMF by affinity chromatography on Blue sepharose CL-6B.

List of potential toxins/enzymes for use in the conjugate of the present invention:

Plant toxins

15 ricin
 abrin
 modeccin
 viscumin
 pokeweed antiviral protein (PAP)
 saporin
20 gelonin
 momoridin
 trichosanthin
 barley toxin
 bryodin

25 **Bacterial toxins**

 pseudomonas exotoxin (PE)
 diphtheria toxin

Fungal toxins

30 α -sarcin
 restrictocin

Drugs

 doxorubicin (also called adriamycin)
 2-pyrrolinodoxorubicin (a more toxic derivative
 of DOX)
35 daunarubicin
 methotrexate
 neocarzinostatin
 mitomycin C
 calicheamicin

vinca alkaloids (vinblastin, vincristine etc)

Enzyme conjugates for subsequent treatment with pro-
drugs

- 5 carboxypeptidase
 alkaline phosphatase

EXAMPLE III

Cell toxicity of an AMF-doxorubicin conjugate

- 10 Autocrine motility factor (AMF) is identical to
phosphohexose isomerase (PHI) (Watanabe, H. et al.
(1996) Cancer Res. 56, 2960-2963) and commercially
available PHI (M.W. 60,000) was conjugated to the cel-
lular toxin doxorubicin (M.W. 580) by glutaraldehyde
15 mediated crosslinking. 2 mg of PHI was mixed with 0.4
mg of doxorubicin in the presence of 0.02% glutaralde-
hyde for 10 minutes at 4°C. Under these conditions
minimal crosslinking of PHI to form high molecular
weight complexes is observed. The reaction mix was
20 passed over a G25 Sephadex column to separate PHI from
the smaller free doxorubicin (Fig. 7). One ml fractions
were collected and the major protein peak absorbing at
280 nm (Peak 1) corresponding to PHI also absorbs at
495 nm, the absorbance maximum of doxorubicin, demon-
25 strating that doxorubicin was successfully conjugated
to PHI. Free doxorubicin eluted more slowly and corre-
sponds to the peak of 495 nm absorbance after fraction
25.

- Fractions 5, 6 and 7 were pooled and concen-
30 trated to 400 μ l. The concentrated fraction had an
OD₂₈₀ of 2.58 and OD₄₉₅ of 0.36. Based on the OD₂₈₀ of
a 1 mg/ml solution of PHI and taking into consideration
the contribution of doxorubicin absorbance at 280 nm,
the approximate concentration of the AMF-Dox fraction
35 was determined to be 3.3 mg/ml.

Rabbit PHI is internalized by murine NIH-3T3 fibroblasts (Benlimame et al., 1998, *Molec. Biol. Cell* 9: 1773-1786) and the ability of the AMF-doxorubicin conjugate to kill metastatic tumor cells was tested with the B16-F10 metastatic murine melanoma cell line. B16-F10 cells were plated at a density of 4,000 cells/cm² and after 24 hours in culture AMF-doxorubicin conjugate was added at a concentration of approximately 0.3, 3, or 30 µg/ml (Fig. 8). After 3 (Expt. 1) or 4 days (Expt. 2) the cultures were fixed and cells remaining attached to the substrate counted. The number of cells remaining attached to the substrate is presented relative to control cells to which no AMF-doxorubicin was added. Increasing concentrations of AMF-doxorubicin is associated with progressive toxicity to B16-F10 melanoma cells demonstrating that AMF conjugated to a cellular toxin can kill tumor cells.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A therapeutical conjugate to specifically kill motile cells, which comprises a first molecule which binds to autocrine motility factor receptor (AMF-R) attached to a second toxic molecule to kill said motile cells.
2. The conjugate of claim 1, wherein said cells are metastatic tumor cells.
3. The conjugate of claim 2, wherein said first molecule is AMF.
4. The conjugate of claim 2, wherein said second molecule is selected from the group consisting of plant toxins, bacterial toxins, fungal toxins, drugs, and enzymes for activating prodrugs.
5. The conjugate of claim 4, wherein said plant toxin is selected from the group consisting of ricin, abrin, modeccin, viscumin, pokeweed antiviral protein (PAP), saporin, gelonin, momoridin, trichosanthin, barley toxin, and bryodin.
6. The conjugate of claim 4, wherein said bacterial toxin is selected from the group consisting of pseudomonas exotoxin (PE), and diphtheria toxin.
7. The conjugate of claim 4, wherein said fungal toxin is selected from the group consisting of α -sarcin, and restrictocin.

8. The conjugate of claim 4, wherein said drug is selected from the group consisting of doxorubicin, 2-pyrrolinodoxorubicin, daunorubicin, methotrexate, neocarzinostatin, mitomycin C, calicheamicin, and vinca alkaloids.

9. The conjugate of claim 4, wherein said enzyme is selected from the group consisting of carboxypeptidase, and alkaline phosphatase.

10. The use of internalization of autocrine motility factor receptor (AMF-R) to target motile cells, which comprises at least one molecule which binds to autocrine motility factor receptor (AMF-R) and is internalized by motile cells.

11. The use of claim 10, wherein said cells are metastatic tumor cells.

12. A method to specifically kill cancer cells in vitro and/or in vivo, which comprises administering an effective amount of the conjugate of any of claims 1-9.

13. The method of claim 12, wherein said cells in vitro are leukemias purging cells.

14. The method of claim 12, wherein said cells in vivo are metastatic tumor cells.

1/6




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/6




FIG. 2




FIG. 3

SUBSTITUTE SHEET (RULE 26)

3/6




FIG. 4

SUBSTITUTE SHEET (RULE 26)

4/6





FIG. 5

SUBSTITUTE SHEET (RULE 26)



5/6



7-5-6

SUBSTITUTE SHEET (RULE 26)

6/6

FIG. 7FIG. 8

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00438

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 10795 A (BURNHAM INST) 19 March 1998 (1998-03-19) abstract page 4, line 11 - page 5, line 11 claims 55,63-65 ---	3-9, 12-14
A	WO 98 18493 A (DEFEO JONES DEBORAH ;FENG DONG MEI (US); GARSKY VICTOR M (US); MER) 7 May 1998 (1998-05-07) abstract page 3, line 30 - page 4, line 2 page 6, line 1 - line 29 claims 1-36 --- -/--	3-9, 12-14

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 August 1999

Date of mailing of the international search report

24 09 99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Taylor, G.M.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00438

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 728 383 A (YOULE RICHARD J ET AL) 17 March 1998 (1998-03-17) abstract column 1, line 15 - column 2, line 17 column 5, line 5 - line 22 claims 1-12 -----	3-9, 12-14
A	WO 94 01777 A (MICHIGAN CANCER FOUNDATION) 20 January 1994 (1994-01-20) abstract page 3, paragraph 1 - page 4, paragraph 1 page 17, paragraph 2 - paragraph 5 claim 1 figure 1 -----	3-9, 12-14
A	WO 88 09797 A (US ARMY) 15 December 1988 (1988-12-15) abstract claim 2 -----	3-9, 12-14

INTERNATIONAL SEARCH REPORT

International application No
PCT/CA 99/00438

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1, 2, 10, 11
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,2,10,11

Present claims 1, 2, 10 and 11 relate to a product or method defined by reference to a desirable characteristic or property, namely

"which binds to autocrine motility factor receptor" (claims 1, 2, 10 and 11)

"is internalised by motile cells" (claims 10 and 11)

The claims cover all products or methods having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products and methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product and method by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to

the conjugates having a first molecule which is AMF, as defined in claim 3; and

the use of such products in methods as defined in claims 12-14

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00438

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9810795 A	19-03-1998	AU 4412297 A EP 0927045 A	02-04-1998 07-07-1999
WO 9818493 A	07-05-1998	AU 5149798 A HR 970566 A NO 992069 A	22-05-1998 31-08-1998 30-06-1999
US 5728383 A	17-03-1998	US 5352447 A US 5208021 A US 5792458 A CA 1338818 A	04-10-1994 04-05-1993 11-08-1993 31-12-1996
WO 9401777 A	20-01-1994	US 5382521 A AU 672808 B AU 4668293 A CA 2139500 A EP 0656114 A JP 8501929 T SE 504759 C SE 9500030 A US 5650500 A US 5541298 A	17-01-1995 17-10-1996 31-01-1994 20-01-1994 07-06-1995 05-03-1996 21-04-1997 10-03-1995 22-07-1997 30-07-1996
WO 8809797 A	15-12-1988	AU 614755 B AU 1803488 A CA 1310902 A EP 0362278 A JP 2851288 B JP 4502143 T US 5604106 A	12-09-1991 04-01-1989 01-12-1992 11-04-1990 27-01-1999 16-04-1992 18-02-1997

Form PCT/ISA/210 (patent family annex) (July 1992)

